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Abstract
Background: Tobacco smoking is a risk factor for multiple diseases, including cardiovascular disease and diabetes.
Many smoking-associated signals have been detected in the blood methylome, but the extent to which these
changes are widespread to metabolically relevant tissues, and impact gene expression or metabolic health,
remains unclear.
Methods: We investigated smoking-associated DNA methylation and gene expression variation in adipose
tissue biopsies from 542 healthy female twins. Replication, tissue specificity, and longitudinal stability of the
smoking-associated effects were explored in additional adipose, blood, skin, and lung samples. We
characterized the impact of adipose tissue smoking methylation and expression signals on metabolic disease
risk phenotypes, including visceral fat.
Results: We identified 42 smoking-methylation and 42 smoking-expression signals, where five genes (AHRR,
CYP1A1, CYP1B1, CYTL1, F2RL3) were both hypo-methylated and upregulated in current smokers. CYP1A1 gene
expression achieved 95% prediction performance of current smoking status. We validated and replicated a
proportion of the signals in additional primary tissue samples, identifying tissue-shared effects. Smoking leaves
systemic imprints on DNA methylation after smoking cessation, with stronger but shorter-lived effects on
gene expression. Metabolic disease risk traits such as visceral fat and android-to-gynoid ratio showed
association with methylation at smoking markers with functional impacts on expression, such as CYP1A1, and
at tissue-shared smoking signals, such as NOTCH1. At smoking-signals, BHLHE40 and AHRR DNA methylation
and gene expression levels in current smokers were predictive of future gain in visceral fat upon smoking
cessation.
Conclusions: Our results provide the first comprehensive characterization of coordinated DNA methylation
and gene expression markers of smoking in adipose tissue. The findings relate to human metabolic health
and give insights into understanding the widespread health consequence of smoking outside of the lung.
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Background
Tobacco smoking is a major environmental risk factor
that predisposes an individual to chronic disease, cancer,
and premature death [1, 2]. Smoking directly affects ex-
posed regions of the lung [3], causes damage in organs
throughout the body, and results in DNA mutations that
have been linked to cancer [4]. The risk effects of smok-
ing extend to multiple diseases, including cardiovascular
and metabolic disease. Smoking cessation has also been
linked to metabolic health complications and is associated
with an increase in weight gain and in metabolic disease
risk factors such as accumulation of visceral fat [5].
Persistent smoking has lasting effects on DNA methy-
lation, and many epigenome-wide association studies
(EWAS) have identified and replicated smoking-related
differentially methylated signals across populations with
the majority found in whole blood samples [6–20], buccal
cells [21], and lung tissue [22, 23]. Most smoking methyla-
tion signals show lower levels of DNA methylation in
current smokers compared to non-smokers, and variable
dynamics upon cessation. Although some alterations per-
sist over decades, smoking cessation can result in methyla-
tion levels reverting to those observed in non-smokers
[13, 16, 18, 24]. However, most ex-smokers exhibit inter-
mediate methylation levels between non-smokers and
current smokers [13, 16, 18, 24]. Methylation levels correl-
ate with the cumulative dose of smoking and are associ-
ated with time since smoking cessation [13, 16, 24, 25].
Smoking can also affect gene expression, as reported in
the human airway epithelium [26, 27], lung tissue [28], al-
veolar macrophages [29], and lung cancer tissue [30].
However, few studies have examined DNA methylation and
gene expression changes concurrently, and these studies
were either conducted with low coverage genome assays
(such as pyrosequencing [30] and HELP assay [8]) or tar-
geted single genes of interest in small sample sizes [8, 30].
Here, we performed the first combined genome-wide
analysis of smoking-related methylation and gene expres-
sion changes across tissues, focusing on adipose tissue. Ex-
ploring the molecular changes induced by smoking in a
metabolically relevant tissue such as adipose tissue is of
value to metabolic health research, because smoking is a
risk factor for metabolic complications and smoking cessa-
tion has been linked to the accumulation of visceral fat.
Here, we identify multiple genes that exhibit both methyla-
tion and expression changes within adipose tissue and
across tissues, showing that smoking leaves a systemic im-
print on DNA methylation and expression variation in the
human body. Our data suggest that smoking leaves a stron-
ger impact on gene expression, while DNA methylation
smoking changes are more stable over time. By linking our
findings to key human phenotypes related to metabolic
health, we identify signals that could add understanding to
some of the wide-ranging risk effects of smoking on meta-
bolic diseases.
Results
Integrated DNA methylation and gene expression
analyses in adipose tissue
Our study design is summarized in Fig. 1. Both DNA
methylation and gene expression profiles were explored in
adipose tissue biopsies from 542 subjects, comprising 54
Fig. 1 Study design. Epigenome-wide and transcriptome-wide association studies were performed in 345 adipose tissue samples, identifying 42
smoking-DMS and 42 smoking-DES where five genes (14 CpG sites) overlapped. The 42 smoking-DMS were replicated in 104 independent subjects
from the LEAP cohort, and the 14 smoking-DMS were further explored in blood, skin, and lung tissue for tissue-shared effects. DNA methylation and
gene expression profiles at the 42 smoking-DMS and 42 smoking-DES were tested for smoking cessation reversibility in 197 ex-smokers. Heritability
and QTL analyses testing genetic and environmental influences on methylation in the 542 adipose samples were also carried out. The final set of
analyses focused on exploring the link between the 42 smoking-DMS and 42 smoking-DES with metabolic phenotypes. Phenotype associations with
smoking-DMS were replicated in 69 Finnish twins. The last set of analyses explored the potential of methylation and gene expression levels at
smoking-DMS and smoking-DES to predict future long-term changes in adiposity phenotypes in individuals who go on to quit smoking
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current smokers, 197 ex-smokers, and 291 non-smokers.
The 197 ex-smokers in our sample were excluded from
analyses investigating methylation differences between
current smokers and non-smokers, but were the focus of
subsequent smoking cessation analyses. DNA methylation
levels at 467,889 CpG sites from the Illumina Infinium
HumanMethylation450 BeadChip were first compared be-
tween current smokers (mean BMI = 26.11 ± 4.66, mean
age = 54.17 ± 8.31) and non-smokers (mean BMI = 26.95
± 4.83, mean age = 59.18 ± 9.58). At a false discovery rate
of 1% (P < 8.37 × 10−7), there were 42 smoking differentially
methylated signals (smoking-DMS) or CpG sites, and
these were located in 29 unique genomic regions compris-
ing of 28 genes and 1 intergenic region (Fig. 2a).
Smoking-DMS are located predominantly in the gene
body (47.6%), extended promoter region (38.1%), 3′UTR
(4.7%), and intergenic region (9.5%), representing an en-
richment of signals in the gene body relative to array com-
position. Using Roadmap annotations (adipose nuclei)
[31], we observed that 16 smoking-DMS (38%) were lo-
cated in enhancers and 9 (21%) were in or near active
transcription start sites (TSS). Of these 25 enhancer or
TSS signals, 9 were flanking bivalent enhancers (n = 3) or
TSS (n = 6). As expected, methylation levels of current
smokers were lower than those in non-smokers in the ma-
jority (90.5%) of the 42 signals (Table 1).
To assess the impact of potential confounders on these
results, we performed two follow-up analyses. First, we
considered the impact of adipose tissue cell-type compos-
ition heterogeneity by also analyzing these data within the
Fig. 2 Coordinated smoking-associated DNA methylation and gene expression changes in adipose tissue. a Manhattan plots of genome-wide
results for methylation (upper panel) and gene expression (lower panel) association with smoking in 345 adipose samples. Smoking-DMS and
smoking-DES are indicated above the 1% FDR line (green dashed line) and are classified by direction of effect for current smokers who have
higher (red dots) or lower (blue dots) methylation or expression levels compared to non-smokers. Genes highlighted by purple blocks represent five
smoking-induced differentially methylated and expressed genes. b Methylation–expression correlation at five genes with coordinated smoking-DMS
and smoking-DES. Pairwise Spearman’s correlation coefficients between methylation and gene expression levels for 54 current smokers (red bars) and
291 non-smokers (blue bars). Asterisk indicates significance at P < 0.05. c Discrimination of current and non-smokers using gene expression levels at
the five overlapping genes. Receiver operating characteristic (ROC) curves are shown for the following combinations of predictors: CYP1A1 gene
expression level (red) and five smoking-DES (black) in the full dataset as an illustrative example, including AUC values from the full dataset
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Table 1 Smoking differentially methylated sites in adipose tissue (42 smoking-DMS)
IlmnID CHR Location Gene name Non-smoker Current smoker Coef. S.E. P value cis-meQTL S*
β (mean ± SD) β (mean ± SD)
cg05951221 2 233284402 2q37.1 0.255 ± 0.054 0.172 ± 0.040 − 1.380 0.108 1.28 × 10−29 rs2853386; 3.87 × 10−8
cg21566642 2 233284661 2q37.1 0.225 ± 0.040 0.167 ± 0.029 − 1.347 0.122 1.87 × 10−23
cg23680900 15 75017924 CYP1A1 0.202 ± 0.036 0.155 ± 0.030 − 1.198 0.118 2.96 × 10−21 O
cg14120703 9 139416102 NOTCH1 0.748 ± 0.045 0.693 ± 0.044 − 1.172 0.118 1.44 × 10−20
cg26516004 15 75019376 CYP1A1 0.696 ± 0.047 0.628 ± 0.058 − 1.258 0.126 1.95 × 10−20 Y
cg10009577 15 75018150 CYP1A1 0.068 ± 0.021 0.050 ± 0.016 − 0.810 0.090 2.48 × 10−17 Y
cg01985595 6 136479501 PDE7B 0.961 ± 0.025 0.936 ± 0.032 − 1.015 0.119 1.09 × 10−15 Y
cg22418620 5 172072885 NEURL1B 0.832 ± 0.049 0.765 ± 0.057 − 1.077 0.127 1.63 × 10−15 rs57285944; 2.15 × 10−8 Y
cg23160522 15 75015787 CYP1A1 0.622 ± 0.033 0.583 ± 0.044 − 0.991 0.122 1.33 × 10−14 Y
cg03636183 19 17000585 F2RL3 0.506 ± 0.040 0.473 ± 0.038 − 0.826 0.103 1.80 × 10−14
cg07992500 2 37896583 CDC42EP3 0.771 ± 0.051 0.719 ± 0.052 − 1.087 0.141 1.88 × 10−13 rs7595854; 1.32 × 10−7
cg12531611 6 11212619 NEDD9 0.909 ± 0.021 0.892 ± 0.024 − 0.855 0.120 1.12 × 10−11 O
cg03646542 5 172076155 NEURL1B 0.689 ± 0.037 0.654 ± 0.035 − 0.880 0.133 1.87 × 10−10 rs7715699; 1.72 × 10−10 Y
cg00353139 15 75017914 CYP1A1 0.034 ± 0.013 0.022 ± 0.010 − 0.787 0.121 4.47 × 10−10 rs11072498; 2.47 × 10−6 Y
cg21124714 11 72983097 P2RY6 0.736 ± 0.037 0.707 ± 0.033 − 0.874 0.136 5.15 × 10−10 Y
cg01940273 2 233284934 2q37.1 0.334 ± 0.045 0.302 ± 0.044 − 0.679 0.105 8.93 × 10−10
cg25648203 5 395444 AHRR 0.503 ± 0.044 0.459 ± 0.040 − 0.825 0.132 1.30 × 10−9
cg20408276 2 38300586 CYP1B1 0.548 ± 0.060 0.499 ± 0.059 − 0.781 0.125 1.61 × 10−9 O
cg20131897 12 52305332 ACVRL1 0.694 ± 0.034 0.673 ± 0.028 −0.693 0.116 5.61 × 10−9 rs1700159; 2.97 × 10−7 Y
cg21611682 11 68138269 LRP5 0.370 ± 0.041 0.336 ± 0.035 −0.734 0.124 8.10 × 10−9
cg19405895 5 407315 AHRR 0.955 ± 0.014 0.942 ± 0.024 −0.768 0.128 8.38 × 10−9 Y
cg05575921 5 373378 AHRR 0.713 ± 0.044 0.682 ± 0.039 − 0.611 0.104 1.07 × 10−8 rs7731963; 3.97 × 10−8
cg13531977 9 112013420 EPB41L4B 0.807 ± 0.035 0.833 ± 0.029 0.831 0.140 1.14 × 10−8 Y
cg00512031 4 5021976 CYTL1 0.880 ± 0.026 0.855 ± 0.028 −0.760 0.129 1.23 × 10−8 chr4:5022470;1.42 × 10−9 Y
cg25189904 1 68299493 GNG12 0.100 ± 0.043 0.064 ± 0.030 − 0.771 0.131 1.48 × 10−8
cg00378510 19 2291020 LINGO3 0.217 ± 0.059 0.181 ± 0.053 −0.781 0.134 1.53 × 10−8 rs12609156; 6.83 × 10−18
cg11554391 5 321320 AHRR 0.065 ± 0.019 0.048 ± 0.014 −0.720 0.125 2.00 × 10−8
cg01802380 13 107865407 FAM155A 0.845 ± 0.030 0.825 ± 0.037 −0.737 0.133 5.69 × 10−8 rs9520326; 1.52 × 10−12 Y
cg14179389 1 92947961 GFI1 0.083 ± 0.030 0.063 ± 0.028 −0.665 0.122 1.07 × 10−7
cg06644428 2 233284112 2q37.1 0.036 ± 0.018 0.024 ± 0.010 − 0.704 0.130 1.61 × 10−7
cg12081267 2 98486185 TMEM131 0.878 ± 0.038 0.858 ± 0.035 − 0.650 0.122 1.97 × 10−7 Y
cg02162897 2 38300537 CYP1B1 0.567 ± 0.060 0.520 ± 0.061 −0.674 0.127 2.89 × 10−7 O
cg11555067 2 99081350 INPP4A 0.725 ± 0.047 0.700 ± 0.046 −0.717 0.138 3.18 × 10−7 rs3754893; 2.27 × 10−7
cg04134818 5 148998446 FLJ41603 0.153 ± 0.026 0.133 ± 0.025 −0.690 0.132 3.26 × 10−7 rs11950259; 7.83 × 10−6 Y
cg03976650 13 77456505 KCTD12 0.667 ± 0.061 0.612 ± 0.067 −0.754 0.143 3.56 × 10−7 Y
cg22851561 14 74214183 C14orf43 0.422 ± 0.041 0.390 ± 0.040 −0.634 0.121 3.92 × 10−7
cg10376100 1 236017278 LYST;MIR1537 0.923 ± 0.036 0.947 ± 0.030 0.615 0.117 4.03 × 10−7 Y
cg04063216 2 14772482 FAM84A 0.071 ± 0.016 0.075 ± 0.019 0.441 0.085 4.39 × 10−7 Y
cg16320419 3 5025570 BHLHE40 0.352 ± 0.052 0.315 ± 0.048 − 0.699 0.135 4.88 × 10−7
cg04135110 5 346695 AHRR 0.339 ± 0.061 0.384 ± 0.065 0.699 0.137 5.34 × 10−7 rs2672748; 3.42 × 10−17
cg20109054 6 31804109 C6orf48;SNORD52 0.091 ± 0.026 0.072 ± 0.023 − 0.659 0.130 7.85 × 10−7 rs3828922; 2.74 × 10−5
cg16721845 11 68518800 MTL5 0.018 ± 0.008 0.014 ± 0.007 − 0.530 0.106 8.37 × 10−7 Y
IlmnID, Illumina probe ID; CHR, chromosome; Location, location of the CpG site (bp); β (mean ± SD), mean and standard deviation of the Illumina beta
methylation levels in the non-smoker and current smoker group; Coef., regression coefficients from the linear mixed effect model, positive values denote
hypermethylation in current smokers and negative values denote hypo-methylation in current smokers; cis-meQTL, top significant cis-meQTL for the CpG site;
S*, adipose tissue-specific effect
Here, we compared our results to one of the biggest smoking-EWAS conducted in blood [20], probes not listed as their significant signals (on their Additional file 2:
Table S2, FDR≤ 0.05) were recorded as “Y” in this table; probes with significant effects in blood in the opposite direction are recorded as “O”
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reference-free EWAS framework [32]. We observed that
the 42 smoking-DMS remained significant at false discov-
ery rate (FDR) of 1%, suggesting that cell composition
within adipose tissue did not have a major impact on our
findings (Additional file 1: Figure S1). Second, habitual
smoking is strongly associated with alcohol consumption
[33], and in our data, current smokers and ex-smokers
have a higher alcohol intake compared to non-smokers
(average alcohol intake = 5.96 (non-smokers), 10.03
(ex-smokers), and 11.67 (current smokers) grams per
day, P = 1.06 × 10−5). Although our smoking analyses
take into account alcohol consumption as a covariate,
it is possible that the smoking-DMS still in part capture
alcohol consumption. To test for the co-occurrence of
differentially methylated signals for smoking and alco-
hol consumption, we performed an alcohol EWAS
adjusting for smoking to compare the results with the
42 smoking-DMS. We observed no significant associ-
ation between alcohol consumption and methylation at
genome-wide significance after adjusting for smoking
in adipose tissue, and only 7 smoking-DMS in AHRR
(cg01802380, cg04134818, cg19405895), CYP1B1 (cg19
405895, cg20408276), FAM84A (cg04063216), and C6or
f48 (cg20109054) surpassed nominal significance (P values
between 0.05 and 0.005).
We next compared RNA-sequencing profiles from the
same tissue biopsy between current smokers and
non-smokers at the gene-based level using RPKM values
across 17,399 genes. At an FDR of 1% (P < 2.86 × 10−5),
there were 42 differentially expressed signals (smo-
king-DES) or genes (Fig. 2a), and 14 of these were up-
regulated in current smokers (Table 2). The strongest
smoking-related expression signal was in the CYP1A1
gene—a lung cancer susceptibility gene, which was also
one of the differentially methylated signals. Gene expres-
sion levels in CYP1A1 were higher in current smokers
compared to non-smokers (Figs. 2a and 3).
Comparison of the FDR 1% genome-wide significant
smoking-DMS and smoking-DES showed overlapping
signals at five genes comprising 14 CpG sites, and these
included AHRR, CYP1A1, CYP1B1, CYTL1, and F2RL3
(Fig. 2a). CpG sites within AHRR, CYP1B1, and F2RL3
were located in the gene body, whereas CpG sites in or
near CYP1A1 and CYTL1 were located 200 kb to 1500 kb
away from the transcription start sites. All five genes were
upregulated in current smokers, and in the majority of
smoking-DMS (93%), current smokers showed lower
methylation levels compared to non-smokers. These pre-
dominantly negative correlations between methylation and
expression at these five genes suggested regulatory effects
(Table 3, Fig. 2b). The methylation-expression correlations
at some of these CpG sites were only observed in current
smokers, and overall correlations were stronger in smokers
compared to non-smokers.
Prediction of smoking status based on DNA methylation
and gene expression
To assess the impact of smoking on DNA methylation
and gene expression within the same analysis framework
and at a comparable scale, we used methylation and ex-
pression changes at these five overlapping genes (14
CpG sites) to predict a subject’s smoking status using a lo-
gistic regression model. We split the overall dataset into
training and validation sets of equal size and report here
the average area under curve (AUC) values from 1000 val-
idation sets. The combination of 14 smoking-DMS levels
and 5 smoking-DES levels resulted in reasonable discrim-
ination of smoking status (AUC: 0.865). Compared to the
prediction results based on 14 smoking-DMS levels alone
(AUC: 0.888), smoking-DES levels are better predictors
(all five genes, AUC: 0.951). This suggests that smoking
leaves a greater impact on gene expression levels, com-
pared to DNA methylation levels at these overlapping
genes. A similar high predictive value can be achieved by
using gene expression levels at just a single gene, CYP1A1
(AUC: 0.952) (Fig. 2c). CYP1A1 was the peak smoking dif-
ferentially expressed gene, with differentially methylated
signals in the promoter, and a negative correlation be-
tween methylation and expression (Fig. 3b).
Adipose-specific and tissue-shared smoking signals
To test if the effects of smoking are shared across tissues,
we first compared our adipose findings to results from
whole blood samples. To this end, we tested for association
between smoking and whole blood genome-wide DNA
methylation (in 569 individuals) and gene expression pro-
files (in 237 individuals), comparing current smokers with
non-smokers. In blood, genome-wide significant results at
FDR 1% for smoking DMS and DES overlapped at four
genes (Additional file 2: Table S1). Altogether, comparison
of FDR 1% significant smoking-DMS results across the adi-
pose and whole blood datasets identified 14 CpG sites that
were genome-wide differentially methylated in both
blood and adipose tissue (Fig. 4a). The 14 tissue-shared
CpG sites fell in eight genes, including GNG12, GFI1,
AHRR, NOTCH1, LRP5, C14orf43, LINGO3, F2RL3, and
in the 2q37.1 intergenic region (Table 4). All of these
sites were previously reported as smoking differentially
methylated sites in blood in previous studies [6–19]
and include AHRR—the most robustly replicated
smoking-methylation signal (Fig. 5a). DNA methylation
changes in two genes (AHRR and F2RL3) that exhibit
both expression and methylation smoking-associated
effects in adipose tissue were also present in the blood
(Figs. 4c and 5b).
We sought to explore the observed tissue-shared me-
thylation effects at the 14 putative tissue-shared CpG
sites in additional datasets including 195 skin tissue
samples from healthy subjects [34] and 168 lung tissue
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Table 2 Smoking differentially expressed genes in adipose tissue (42 smoking-DES)
ID CHR Name Coef. S.E. P value cis eQTLs
ENSG00000140465.7 15 CYP1A1 1.899 0.103 5.37 × 10−51 rs35213055; 1.53 × 10−6
ENSG00000138061.7 2 CYP1B1 1.373 0.131 2.83 × 10−21
ENSG00000144331.14 2 ZNF385B − 1.257 0.134 1.53 × 10−18 rs9288034; 8.33 × 10−5
ENSG00000179151.6 15 EDC3 1.167 0.129 3.10 × 10−17
ENSG00000063438.12 5 AHRR 1.059 0.149 6.03 × 10−12
ENSG00000175267.8 16 VWA3A 0.932 0.139 2.18 × 10−10
ENSG00000170381.7 7 SEMA3E − 0.821 0.137 8.35 × 10−9 chr7:83264879;1.22 × 10−10
ENSG00000170891.6 4 CYTL1 0.807 0.142 2.82 × 10−8
ENSG00000187486.5 11 KCNJ11 − 0.859 0.148 3.27 × 10−8
ENSG00000168280.11 2 KIF5C − 0.813 0.145 4.74 × 10−8
ENSG00000006016.5 19 CRLF1 0.769 0.146 2.53 × 10−7 chr19:18717389; 2.63 × 10−6
ENSG00000127533.2 19 F2RL3 0.782 0.147 2.89 × 10−7
ENSG00000149294.11 11 NCAM1 − 0.715 0.135 3.03 × 10−7 rs17510563; 2.01 × 10−7
ENSG00000120693.9 13 SMAD9 − 0.733 0.140 4.76 × 10−7
ENSG00000169116.7 4 PARM1 − 0.686 0.133 6.76 × 10−7
ENSG00000154330.6 9 PGM5 − 0.716 0.147 1.72 × 10−6
ENSG00000162430.12 1 SEPN1 − 0.663 0.137 1.82 × 10−6
ENSG00000154721.9 21 JAM2 − 0.667 0.136 2.23 × 10−6
ENSG00000177303.4 17 CASKIN2 − 0.669 0.140 2.90 × 10−6
ENSG00000157404.10 4 KIT 0.708 0.150 3.31 × 10−6
ENSG00000161544.4 17 CYGB 0.621 0.131 3.42 × 10−6
ENSG00000154065.9 18 ANKRD29 − 0.684 0.144 3.49 × 10−6
ENSG00000176907.3 8 C8orf4 − 0.714 0.151 3.56 × 10−6
ENSG00000168032.4 3 ENTPD3 − 0.674 0.140 3.86 × 10−6 rs34158576; 7.60 × 10−6
ENSG00000162367.6 1 TAL1 − 0.665 0.142 4.17 × 10−6
ENSG00000180785.8 11 OR51E1 − 0.655 0.142 6.82 × 10−6 rs11033126; 3.78 × 10−10
ENSG00000164010.9 1 ERMAP − 0.690 0.154 9.50 × 10−6
ENSG00000068078.12 4 FGFR3 − 0.643 0.143 9.68 × 10−6 rs744658; 9.68 × 10−8
ENSG00000246223.4 14 C14orf64 − 0.633 0.142 1.44 × 10−5 rs75700090; 2.00 × 10−5
ENSG00000145506.9 5 NKD2 0.616 0.140 1.46 × 10−5
ENSG00000161649.7 17 CD300LG − 0.648 0.147 1.48 × 10−5
ENSG00000163873.5 1 GRIK3 − 0.643 0.146 1.50 × 10−5
ENSG00000053747.9 18 LAMA3 − 0.652 0.148 1.57 × 10−5
ENSG00000183733.6 2 FIGLA 0.406 0.093 1.57 × 10−5
ENSG00000164736.5 8 SOX17 − 0.629 0.144 1.64 × 10−5
ENSG00000106078.12 7 COBL − 0.680 0.155 1.65 × 10−5
ENSG00000120156.14 9 TEK − 0.610 0.140 1.67 × 10−5
ENSG00000178726.5 20 THBD − 0.612 0.141 2.00 × 10−5
ENSG00000177675.4 12 CD163L1 0.635 0.148 2.40 × 10−5
ENSG00000136828.13 9 RALPGS1 − 0.646 0.151 2.60 × 10−5
ENSG00000135914.4 2 HTR2B 0.613 0.144 2.82 × 10−5
ENSG00000090530.5 3 LEPREL1 − 0.617 0.145 2.86 × 10−5 rs6768989; 1.10 × 10−9
ID, Ensemble ID; CHR, chromosome; Coef., regression coefficients from the linear mixed effect model, positive values reflect higher expression in current smokers
and negative values represent lower expression in current smokers; eQTL, expression quantitative trait locus
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samples from subjects affected with lung cancer. Four of
the 14 CpG sites validated in the skin in the intergenic
region 2q37.1 (cg05951221, cg06644428, and cg2156
6642) and in AHRR (cg05575921). Furthermore, the ma-
jority (n = 13) of the 14 tissue-shared CpG sites had
lower methylation levels in current smokers compared
to non-smokers in both lung and skin methylation data-
sets, indicating a consistent direction of effect, which
was not nominally significant (Table 4, Additional file 2:
Table S2). In lung tissue from subjects affected with lung
cancer, we validated 3 of the 14 CpG sites in the intergenic
region 2q37.1 (cg21566642 and cg05951221) and in the
AHRR gene (cg05575921) at a Bonferroni-corrected P
value of 3.57 × 10−3 (Additional file 2: Table S2). The
smoking-DMS effects observed across tissues were similar
for CpG sites in the 2q37.1 region, while the smoking ef-
fect was much greater in blood at cg05575921 in AHRR
(see Table 4, Fig. 4b).
In contrast to the methylation results, gene expression
signals showed minimal evidence for tissue-shared im-
pacts. Comparing our FDR 1% genome-wide smoking-
DES across adipose and blood datasets showed that only
AHRR was significantly upregulated in current smokers
across both tissues (Fig. 5c). AHRR was the only signal
that showed both differential methylation and expression
changes across all of the datasets that we explored in this
study, including blood, adipose, skin, and lung tissue.
A proportion of our smoking-DMS and most of our
smoking-DES results appear to be adipose-specific.
However, the sample size of the datasets used to explore
tissue specificity in gene expression was much lower
compared to that used for methylation; therefore, power
to detect tissue-shared effects differs across the data
types. Furthermore, we are limited by access to available
multi-tissue datasets for follow-up, and further investiga-
tion of published findings reveals that some of our
smoking adipose-specific signals have previously been
detected in other tissues [20] For example, one of our
peak results at CYP1A1 showed methylation changes
only in adipose tissue and not in the blood (Fig. 4), but
has previously been reported as a smoking-methylation
signal in blood [20], lung tissue [30, 35], cord blood
[36], and placenta [37, 38]. Unlike the persistent
tissue-shared effects identified in other smoking-DMS
such as signals in AHRR and 2q37.1, we found that
current smokers have lower CYP1A1 methylation
levels in adipose, skin, and lung tissue, but not in
blood [20], placenta, and cord blood samples [36],
overall suggesting that smoking may have contrasting
effects, resulting in hyper- or hypo-methylation in dif-
ferent tissues (Fig. 4b). A similar contrast in direction
of smoking methylation effects is observed at smoking-
DMS in NEDD9 and CYP1B1 across adipose tissue and in
blood (Table 1).
Fig. 3 Smoking-associated DNA methylation and gene expression patterns at CYP1A1. a coMET plot [90] describing the genomic region of
epigenome-wide association between smoking and CYP1A1 methylation (top panel), along with functional annotation of the region (middle
panel), and pattern of co-methylation at the 34 CpG sites of CYP1A1 (bottom panel). b DNA methylation and gene expression changes with
respect to smoking cessation. Methylation (at cg23680900) and gene expression levels are shown for five smoking status categories: current
smokers (red); subjects who quit within 1 year, subjects who quit between 1 and 5 years, and subjects who quit over 5 years at the time of methylation
sampling (gray); and non-smokers (blue). X-axis labels include the proportion of subjects who reverted in each smoking quit year category. c CYP1A1
methylation associations with adiposity phenotypes, visceral fat mass (VFM), and android-to-gynoid fat ratio (AGR). DNA methylation levels at three CpG
sites (cg23160522, cg23680900, and cg10009577 in CYP1A1) are shown against adiposity phenotypes in current (red) and non-smokers (blue)
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Replication of adipose smoking methylation signals
We pursued replication of the adipose tissue smoking-
DMS in an independent dataset of 104 participants from
the LEAP cohort, within the New England Family Study
(mean BMI 30.9 ± 7.03, mean age 47 ± 1.7, 48% male),
described in detail elsewhere [39]. These individuals
were not affected with common diseases and had avail-
able adipose biopsy methylation profiles for 46 current
smokers and 58 non-smokers. We found that the
smoking-methylation direction of association was con-
sistent at all 42 adipose smoking-DMS (Additional file 2:
Table S3), and 25 of these also surpassed nominal sig-
nificance in the replication dataset (P = 0.05). At a more
stringent threshold, the replication signal was signifi-
cant at 13 sites, surpassing Bonferroni-adjusted P value
for the replication analysis (P = 1.19 × 10−3).
Signatures of smoking cessation
We next assessed the effect of smoking cessation on the
observed adipose DNA methylation and gene expression
signals in ex-smokers from the discovery cohort. We
considered reversal of smoking methylation or expres-
sion signals, that is, the longitudinal change in methyla-
tion to reach levels observed in non-smokers. We
quantified the number of subjects who reverted to 25%
of the change in methylation towards non-smokers, and
estimated the proportion of subjects who reverted over
time (in smoking-quit years), using the same approach
in gene expression (see the “Methods” section).
We explored reversal patterns in adipose tissue at both
the 42 smoking-DMS (Additional file 1: Figure S2) and
42 smoking-DES (Additional file 1: Figure S3) and fo-
cused on the five differentially methylated and expressed
genes (14 CpG sites), where the average number of
smoking-quit years was 24.8 (± 13.21) years among 197
ex-smokers. Overall, a rapid rate of reversal was ob-
served in the first 10 years after smoking cessation, after
which only subtle changes were detected in both methy-
lation and gene expression. In the expression adipose
data, ex-smokers showed a > 50% reversal rate 1 year
after smoking cessation and reached > 85% reversal after
10 years (Additional file 1: Figure S3). In comparison,
slower reversal was observed in the methylation dataset
(Additional file 1: Figure S2). Among the 14 CpG sites,
only three (two at AHRR and one at CYP1A1) showed
a 50% reversal rate 1 year after cessation, while the
remaining signals showed between 17 and 33% reversal
(Figs. 3b and 5c, Additional file 1: Figure S3). Even
after > 40 years of smoking cessation, a proportion of
smoking-DMS (n = 12; 29%) showed less than 40% re-
versal (Additional file 1: Figure S3). This suggests that
smoking leaves a longer lasting influence on DNA
methylation levels than on gene expression levels after
smoking cessation.
Controlling for genetic variation
Previous studies have shown heritable impacts on smok-
ing behavior and nicotine addiction [40–43]. We ex-
plored the impact of genetic variation on the identified
smoking methylation signals. Of the 42 smoking-DMS,
14 CpG sites had genome-wide significant meQTLs in
cis in adipose tissue (Table 1). Of the 14 tissue-shared
smoking-DMS, two signals in 2q37.1 and one in
LINGO3 had meQTLs in cis in adipose tissue, and three
signals in AHRR and one in F2RL3 had meQTLs in cis
in blood samples.
Table 3 Correlation between DNA methylation and gene expression
Gene name IlmnID CHR Location ID r P value
CYP1B1 cg20408276 2 38300586 ENSG00000138061.7 − 0.171 1.39 × 10−3
CYTL1 cg00512031 4 5021976 ENSG00000170891.6 − 0.176 1.03 × 10−3
AHRR cg25648203 5 395444 ENSG00000063438.12 − 0.167 1.80 × 10−3
AHRR cg19405895 5 407315 ENSG00000063438.12 − 0.134 1.29 × 10−2
AHRR cg05575921 5 373378 ENSG00000063438.12 − 0.060 0.2633
AHRR cg11554391 5 321320 ENSG00000063438.12 − 0.216 5.37 × 10−5
AHRR cg04135110 5 346695 ENSG00000063438.12 0.279 1.31 × 10−7
AHRR cg24980413 5 346987 ENSG00000063438.12 0.252 2.10 × 10−6
CYP1A1 cg23680900 15 75017924 ENSG00000140465.7 − 0.329 3.94 × 10−10
CYP1A1 cg26516004 15 75019376 ENSG00000140465.7 − 0.298 1.70 × 10−8
CYP1A1 cg10009577 15 75018150 ENSG00000140465.7 -0.266 5.22×10-7
CYP1A1 cg23160522 15 75015787 ENSG00000140465.7 − 0.299 1.48 × 10−8
CYP1A1 cg00353139 15 75017914 ENSG00000140465.7 − 0.222 3.22 × 10−5
F2RL3 cg03636183 19 17000585 ENSG00000127533.2 − 0.130 0.0159
IlmnID, Illumina probe ID; CHR, chromosome; Location, Illumina probe location (bp); ID, Ensemble ID; r, Spearman’s correlation coefficients between methylation
and gene expression data (n = 345)
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Given our observed genetic influences on smoking-
DMS, we asked if previously reported genetic variants
associated with smoking behavior [42] or nicotine me-
tabolism [43] could impact DNA methylation levels in
adipose tissue. We first focused on common genetic var-
iants that were previously associated with smoking
phenotypes in the largest smoking genetic association
study to date (n = 15,907) [42]. We observed that all gen-
etic variants previously strongly linked to smoking be-
havior (14 SNPs) [42] had an impact on adipose DNA
methylation levels in cis (Additional file 2: Table S4). We
then explored a recently reported association between
Fig. 4 Tissue-shared and adipose-specific smoking signals. a Tissue-shared DNA methylation effects across adipose tissue and whole blood. The
bar-plot shows the -log10 P value of the 42 smoking-DMS in adipose samples (blue), and the corresponding P value in the blood samples (red
bars). Gene names in bold denote significantly associated genes in both tissues. b Tissue-shared and tissue-specific DNA methylation effects for
adipose tissue, whole blood, skin, and lung cancer tissue at 2q37.1, AHRR, and CYP1A1. Each bar represents the coefficient estimate from smoking-
EWAS with standard error bars. Positive values indicate a hypermethylation in current smokers. Colors reflect tissues, with coefficients in adipose
(blue), blood (red), skin (gray), and lung tissue (yellow). N.S. indicates non-significance. c Examples of smoking effects that are tissue-shared and
tissue-specific across adipose (blue) and blood (red) samples in our datasets, including adipose-specific (CYP1A1 in our dataset) and tissue-shared
(2q37.1 and F2RL3) smoking-DMS
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a cluster of SNPs on chromosome 19 and nicotine
metabolism, where the same genetic variants were
also associated with blood DNA methylation levels in
the same region as meQTLs [43]. We replicate the
chromosome 19 meQTL findings in our adipose DNA
methylation data at CpGs in genes CYP2A7, ENGL2,
and LTBP4 (Additional file 2: Table S5), suggesting
that these are strong genetic impacts on DNA
methylation that are shared across tissues. Taken to-
gether, these genetic-methylation association results
provide additional support for the hypothesis that
some of the observed genetic impacts on smoking
behavior and nicotine metabolism may be mediated
by DNA methylation.
Table 4 Tissue-shared smoking-induced differentially methylated sites in cancer-free subjects
IlmnID CHR Location Gene name Adipose tissue (n = 345) Blood samples (n = 567) Skin tissue (n = 195)
Coef. P value Coef. P value Coef. P value
cg25189904 1 68299493 GNG12 − 0.771 1.48 × 10−8 − 0.974 6.92 × 10−18 − 0.434 1.58 × 10−2
cg14179389 1 92947961 GFI1 − 0.665 1.07 × 10−7 − 0.404 4.74 × 10−6 − 0.408 1.89 × 10−2
cg06644428 2 233284112 2q37.1 − 0.704 1.61 × 10−7 − 0.864 1.76 × 10−19 − 0.641 3.39 × 10−4
cg05951221 2 233284402 2q37.1 − 1.38 1.28 × 10−29 − 1.471 3.65 × 10−60 − 1.161 6.13 × 10−13
cg21566642 2 233284661 2q37.1 − 1.347 1.87 × 10−23 − 1.491 9.67 × 10−61 − 1.138 4.83 × 10−11
cg01940273 2 233284934 2q37.1 − 0.679 8.93 × 10−10 − 1.415 3.17 × 10−52 − 0.302 3.09 × 10−2
cg11554391 5 321320 AHRR − 0.72 2.00 × 10−8 − 0.694 8.10 × 10−12 − 0.494 4.91 × 10−3
cg05575921 5 373378 AHRR − 0.611 1.07 × 10−8 − 1.672 2.45 × 10− 80 − 0.982 7.24 × 10−8
cg25648203 5 395444 AHRR − 0.825 1.30 × 10−9 − 0.937 3.50 × 10−22 − 0.398 7.29 × 10−3
cg14120703 9 139416102 NOTCH1 − 1.172 1.44 × 10−20 − 0.352 1.84 × 10−6 − 0.423 8.69 × 10−3
cg21611682 11 68138269 LRP5 − 0.734 8.10 × 10−9 − 0.874 4.23 × 10−20 0.075 6.38 × 10−1
cg22851561 14 74214183 C14orf43 − 0.634 3.92 × 10−7 − 0.5 5.24 × 10−7 − 0.326 7.07 × 10−2
cg00378510 19 2291020 LINGO3 − 0.781 1.53 × 10−8 − 1.478 3.59 × 10−62 − 0.133 4.66 × 10−1
cg03636183 19 17000585 F2RL3 − 0.826 1.80 × 10−14 − 0.466 2.37 × 10−7 − 0.372 1.45 × 10−2
IlmnID, Illumina probe ID; CHR, chromosome; Location, Illumina probe location (bp); Coef., regression coefficients from the linear mixed effect model, positive
values denote hypermethylation in non-smokers and negative values denote hypermethylation in current smokers
Fig. 5 Tissue-shared smoking-associated DNA methylation and gene expression patterns at AHRR. a coMET plot [49] of the association between
66 AHRR CpG sites and smoking. Top panel shows the -log10P value of the association; the middle panel shows genomic annotation; and the
lower panel shows co-methylation patterns based on Spearman correlation coefficients. b Tissue-shared and tissue-specific methylation signals
across CpG sites in the AHRR gene region in adipose (blue) and blood samples (red). c DNA methylation and gene expression levels with respect
to smoking cessation. Methylation and gene expression levels are shown for five different smoking status categories: current smokers (red);
subjects who quit within 1 year, subjects who quit between 1 and 5 years, and subjects who quit over 5 years at the time of methylation
sampling (gray); and non-smokers (blue). X-axis labels include the proportion of subjects who reverted in each smoking quit year category
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Impacts on metabolic health and disease risk
Given the wide-ranging effects of smoking on human
disease, we explored the links between the identified
adipose methylation and expression smoking signals
and phenotypes that are major risk factors for meta-
bolic disease. Three metabolic disease risk pheno-
types—total fat mass (TFM), visceral fat mass (VFM),
and android-to-gynoid fat ratio (AGR)—were profiled
using dual X-ray absorptiometry in 288 subjects with
adipose methylation and expression profiles. We
assessed the association of the 42 smoking-DMS and 42
smoking-DES with these adiposity phenotypes using a
twofold approach.
First, we tested for association between adipose methy-
lation levels at the 42 smoking-DMS and the three phe-
notypes, adjusting for covariates including age, BMI, and
smoking. We observed that smoking-DMS in CYP1A1
and NOTCH1 were significantly associated with mea-
sures of metabolic disease risk. First, methylation levels
at three CpG sites in CYP1A1 were significantly associ-
ated with VFM and AGR, either as main effects
(cg23160522 and VFM, beta = 1.35 × 10−3, SE = 3.03 × 10−3,
P = 4.35 × 10−7; cg23680900 and AGR, beta = − 1.59, SE =
0.44, P = 6.58 × 10−6) or taking into account interactions
(cg10009577 and AGR, P = 5.50 × 10−4), where current
smokers and non-smokers have different patterns of associ-
ation between DNA methylation at CYP1A1 cg10009577
and AGR (Fig. 3c). Probe cg10009577 is located in the
CYP1A1 promoter, suggesting gene regulatory impacts on
CYP1A1 expression levels. Correspondingly, we observed a
nominally significant association between CYP1A1 gene ex-
pression and VFM (Fig. 3c), where current smokers and
non-smokers have different patterns of association (P =
0.042). A significant negative association between DNA
methylation levels and AGR was also observed with
cg14120703 in NOTCH1 (beta = − 1.80, SE = 0.43, P =
1.07 × 10−7). We pursued replication of these associations
in an independent sample of 69 younger Finnish twins with
adipose tissue Illumina 450K methylation profiles. We rep-
licated the overall negative association between CYP1A1
cg10009577 and AGR (discovery sample beta = − 0.95,
SE = 0.31; replication sample beta = − 0.58, SE = 0.25,
P = 0.02) and observed a similar direction of inter-
action effects, which did not reach nominal significance
in the replication sample (Additional file 2: Table S5).
We performed similar analyses with the 42 smoking-
DES and observed main effects at F2RL3 on the three
phenotypes (VFM beta = − 1.5 × 10−3, SE = 3.78 × 10−4,
P = 7.8 × 10−4; AGR beta = 2.3, SE = 0.56, P = 4.5 × 10−5;
TFM beta = 1.6 × 10−3, SE = 3.9 × 10−4, P = 5.8 × 10−5),
and OR51E1 on VFM (beta = − 1.5 × 10−3, SE = 3.78 ×
10−4, P = 7.8 × 10−4) and AGR (beta = − 2.85, SE = 0.51,
P = 3.1 × 10−8). We did not observe significant evidence
for interaction effects in the gene expression results.
In the second set of phenotypic analyses, we explored
the role of the 42 smoking-DMS and 42 smoking-DES
on weight gain after smoking cessation. Recent studies
have reported not only a gain in weight on smoking
cessation, but also an increase in visceral fat [5]. We
considered adiposity phenotypes in 246 of the individ-
uals in our study at two time points, where time point
1 was the initial adipose DNA methylation profiling
and phenotype measurement, and time point 2 was a
phenotype measurement on average 5 years later. We
found that current smokers who go on to quit smoking
over this 5-year interval show a gain in adiposity across
all phenotypes (Fig. 6a), and this effect is also observed
in individuals who quit within up to 4 years at time
point 1. However, our data suggests that this gain in
adiposity is not long lasting, because we do not observe
this effect in the group of ex-smokers who had quit for
> 5 years at time point 1. In comparison, there were no
major phenotype changes within constant smokers
(current smokers at both time points) or never smokers
(non-smokers at both time points) across the two time
points.
We tested if the 42 smoking-DMS and 42 DES in adi-
pose tissue could predict future changes in adiposity
upon smoking cessation, focusing on visceral fat accu-
mulation as the major risk factor for the development of
adiposity-related metabolic diseases. Based on the phe-
notype results (Fig. 6a), we compared two groups of in-
dividuals: first, the combined group (n = 18) of current
smokers at the time of methylation profiling (time
point 1) who subsequently quit smoking (n = 5), and in-
dividuals who had quit within 1–4 years at time point 1
(n = 13); and second, the combined group (n = 228) of
ex-smokers who had quit for > 5 years at time point 1
(n = 92), as well as constant smokers (n = 12) and never
smokers (n = 124) across the two time points. We
assessed the impact of methylation or expression at the
42 smoking-DMS (Additional file 1: Figure S4) and 42
smoking-DES (Additional file 1: Figure S5) on future
changes in visceral fat, selecting results that showed
significantly different patterns of association in the two
groups of 18 and 228 subjects.
After Bonferroni correction for multiple testing, we
found one DMS and one DES significantly associated
with future changes in visceral fat, where a strong asso-
ciation effect was only observed in the group 18 sub-
jects. This group consists of current smokers who go on
to quit smoking (n = 5) and recent ex-smokers who re-
main ex-smokers (n = 13), and where all subjects exhibit
a gain in adiposity over time. The first signal was ob-
served in cg16320419 in BHLHE40 (methylation by
group interaction term P = 9.3 × 10−4), where methyla-
tion levels in current smokers or recent ex-smokers ex-
plain 35.5% of the variation in future gain in visceral fat
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(Fig. 6b). The second signal was observed in AHRR (gene
expression by group interaction term P = 4.7 × 10−5),
where gene expression levels in current smokers or recent
ex-smokers explain 44% of the variation in future gain in
visceral fat (Fig. 6c). The results were similar after correct-
ing for smoking years and years since smoking cessation.
Discussion
Tobacco smoking is a major disease risk factor. Our
study is the first to identify smoking-associated DNA
methylation and gene expression changes in adipose tissue
in humans. Approximately 30% of the identified smoking-
methylation signals showed significant coordinated changes
in gene expression levels in five genes, giving insights into
the cascade of molecular events that are triggered in re-
sponse to smoking, toxin exposure, and nicotine metabol-
ism. At least a third of smoking-methylation signals (in
nine genomic regions) were shared across tissues, showing
that smoking leaves tissue-shared signatures. Given that
our target tissue was adipose, we considered the impact
of the identified smoking methylation and expression
signals on metabolic disease risk. Significant associa-
tions were observed between visceral fat and
android-to-gynoid fat ratio and several smoking-methyla-
tion and expression markers. Furthermore, methylation
and expression levels at BHLHE40 and AHRR in current
smokers or recent ex-smokers were predictive of future
gain in visceral fat observed after smoking cessation. Our
findings provide a first comprehensive assessment of
methylation and expression changes related to
smoking in adipose tissue, with insights for metabolic
health and disease risk.
Coordinated smoking methylation and expression
changes overlapped at five genes (AHRR, CYP1A1,
CYP1B1, CYTL1, and F2RL3), which include well-known
and strongly replicated smoking-methylation signals,
such as AHRR and F2RL3. Some of these genes have
previously been linked to human phenotypes. For ex-
ample, GWAS associations have been reported with
multiple diseases and traits, such as drinking behavior
(CYTL1) [44], cystic fibrosis severity (AHRR) [45], caf-
feine consumption (CYP1A1) [46], and diastolic blood
pressure (CYP1A1) [47], and methylation levels at AHRR
have been linked to multiple phenotypes including lung
function [48] and BMI [49]. At the five overlapping
genes, methylation levels were predominantly negatively
correlated with expression levels. CpG sites in AHRR,
CYP1B1, and F2RL3 were located on the gene body,
whereas those in CYTL1 and CYP1A1 were in the pro-
moter. Our results are consistent with the expectation
that promoter-based CpG sites negatively associate with
gene expression [50–52]. Studies have reported both
positive and negative correlations between methylation
and expression for CpG sites in the gene body [53–56].
DNA methylation sites in the gene body that are nega-
tively associated with expression levels may be located in
alternative promoters that regulate the expression of
particular isoforms.
CYP1A1, or cytochrome P4501A1, is a lung cancer sus-
ceptibility gene. Although in our data, CYP1A1 smoking
Fig. 6 Smoking-DMS and smoking-DES relate to future changes in visceral fat mass on smoking cessation. a Adiposity phenotype changes over a
5-year time period between time point 1 (2007–2008) and time point 2 (2012–2013). Adiposity phenotypes include BMI, total fat mass (TFM),
android-to-gynoid fat ratio (AGR), and visceral fat mass (VFM). Phenotype changes are shown for five categories of subjects: current smokers at
the two time points (S-S, n = 12), current smokers at time point 1 who quit smoking by time point 2 (S-E, n = 5), ex-smokers (who quit smoking
within 1–5 year) at time point 1 who remain ex-smokers at time point 2 (E1-E5, n = 13), ex-smokers who quit > 5 years at time point 1 who
remain ex-smokers at time point 2 (E5+, n = 92), and non-smokers at both time points (N-N, n = 124). b Left panel shows the association between
DNA methylation levels at cg16320419 in BHLHE40 and future changes in visceral fat mass in 18 subjects in categories S-E and E1-E5 (red points),
compared to all remaining subjects (gray points). Right panel shows methylation cessation patterns at cg16320419 in BHLHE40. c Association
between DNA methylation (left panel, red points) and gene expression (right panel, blue points) in AHRR with future changes in visceral fat mass
in 18 subjects in categories S-E and E1-E5, compared to all remaining subjects (gray points)
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signals appear adipose-specific, independent studies have
reported links to smoking in multiple tissues. CYP1A1
smoking-associated methylation signals are present in the
lung in the fetus [57] and in adults [30, 35]. In adults, ef-
fects are observed in normal lung tissue from lung cancer
patients at both the CYP1A1 promoter [35] and enhancer
[30], which is also differentially methylated between nor-
mal tissue and lung tumor tissue [30]. A recent large-scale
meta-analysis of smoking methylation signals in blood also
reported a moderate effect at CYP1A1 [20]. Maternal to-
bacco use was also associated with alterations in promoter
methylation of placental CYP1A1, and these changes were
correlated with CYP1A1 gene expression and fetal growth
restriction [58]. Furthermore, CYP1A1 gene expression is
downregulated by AHRR. CYP1A1 is inducible by agonists
of the aryl hydrocarbon receptor (AhR), which include en-
vironmental pollutants and components of cigarette
smoke. Following activation of AhR by an agonist in the
cytoplasm, the AhR-ligand complex translocates to the
nucleus, where it dimerizes with the aryl hydrocarbon re-
ceptor nuclear translocator (ARNT) [59]. This heterodi-
mer binds to the xenobiotic response element (XRE) site
of CYP1A1 in the upstream enhancer region, which acti-
vates transcription. CYP1A1 metabolizes drug molecules
and environmental pollutants, including polycyclic aro-
matic hydrocarbons, dioxin, and benzo(α)pyrene, into
highly reactive intermediates. These derivatives can bind
to DNA and form adducts, which may contribute to car-
cinogenesis [60]. AhR, in a complex with xenobiotic com-
pounds and ARNT, induces CYP1A1 expression, which
subsequently detoxifies toxic components of cigarette
smoke. AHRR suppresses the effects of AhR through bind-
ing to ARNT. Hypo-methylation of AHRR and increased
AHRR expression may therefore reduce cellular responses
to smoking, potentially through CYP1A1 [61]. However,
our findings of increased gene expression levels at both
AHRR and CYP1A1 in current smokers suggest that
smoking-induced AHRR changes do not impact the
CYP1A1 response to smoking in adipose tissue. The
smoking effects at CYP1A1 in our study appear to be
adipose-specific; therefore, these observations do not ex-
tend to blood, skin, or lung samples.
In addition to CYP1A1, other smoking signals that
we identify in this study have also been previously
linked to lung cancer. CYP1B1 differentially methyl-
ated effects have been reported for smoking, for lung
cancer, and for age at cancer diagnosis in non-small
cell lung carcinoma (NSCLC) samples [62]. Several of
our smoking signals were previously reported to be
differentially methylated in lung adenocarcinoma tumor
and matched non-tumor tissue [63]. These included two
of our top smoking-DMS, CYTL1 and ACVRL1, and seven
of our top smoking-DES, CYTL1, JAM2, CYGB, TAL1,
GRIK3, SOX17, and TEK.
In line with previous studies, we observe that genetic
variation can impact the smoking-DMS, with potential
implications for genotype influences on the rates of
toxin elimination and nicotine metabolism in the human
body. Importantly, we observe that all of the major
smoking genetic variants detected in the largest smoking
GWAS to date appear to influence DNA methylation
levels in cis. These findings strongly suggest that DNA
methylation may mediate some of the effects of genetic
influences on smoking behavior, toxin elimination, or
nicotine metabolism. We also replicate results from a
genome-wide association study of nicotine metabolite
ratio, identifying a 4.2-Mb region on chromosome 19q13
where GWAS SNPs were also associated with DNA
methylation levels [43]. Taken together, these findings
suggests some of the observed genetic impacts on smok-
ing behavior and nicotine metabolism may be mediated
by DNA methylation and that such effects are robust
and shared across tissues.
Our analyses specifically in ex-smokers show variability
in the extent of signal reversal over time, which is consist-
ent with previous findings. We observe an overall trend
towards at least partial reversal at most of the identified
smoking-associated signals. Importantly, our study is the
first to show that this trend is also observed in gene ex-
pression levels. Our findings suggest that smoking has a
longer lasting influence on the methylome compared to
the transcriptome, where the majority of reversal effects
occur within the first year after smoking cessation.
The smoking-methylation signals were assessed for
association with adiposity phenotypes that constitute
major metabolic disease risk. Significant associations
were observed between visceral fat mass and android-
to-gynoid fat ratio with methylation levels at smoking
markers with functional impacts on gene expression,
such as CYP1A1 with replication, and in signals that
were shared across tissues, such as NOTCH1. Associa-
tions were also detected with smoking-DES. These re-
sults may help improve our understanding of how
smoking impacts metabolic health, and to explore this
further, we considered smoking effects on future changes
in metabolic phenotypes on smoking cessation. Visceral
fat has a strong association with obesity-related metabolic
diseases, such as type 2 diabetes and cardiovascular
disease [64, 65] and is a major metabolic disease risk fac-
tor. At smoking markers BHLHE40 and AHRR, DNA
methylation and gene expression levels in current smokers
were predictive of future gain in visceral fat observed after
smoking cessation. Although the sample size of current
smokers who go on to quit smoking in our data is modest,
these findings provide an interesting insight into potential
molecular mechanisms mediating environmental effects
on metabolic disease risk and require replication in larger
samples.
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A limitation to our study is partial correction for the
influence of expected covariates. These include, first, alco-
hol consumption, which co-occurs with smoking. In our
co-occurrence analyses, none of the alcohol-associated
CpG sites reached genome-wide significance after adjust-
ing for smoking. In a previous alcohol EWAS in blood,
Liu et al. [66] also found that the effect size of the majority
alcohol-DMS was not affected by smoking status suggest-
ing that despite their co-occurrence, smoking and alcohol
impact DNA methylation in different aspects. A related
question is optimal correction for cell composition in adi-
pose tissue. Since we only had access to subcutaneous adi-
pose tissue biopsies, rather than isolated cell subtypes, we
corrected for cell composition by using the analytical ap-
proach within the reference-free EWAS [32] framework
and found that the majority of results remained largely
unchanged. However, it is possible that this does not
fully capture the effect of a heterogeneous population
of cells as a confounder. Some of the smoking-DMS
such as BHLHE40, which was also found to be predict-
ive of future gain in visceral fat, may reflect cell-specific
methylation profiles. BHLHE40 was previously reported
to be hypo-methylated in activated NK cells (but not in
naive NKs, T, and B cells) [67] and a similar trend was
observed for AHRR [67]. One interpretation of these
findings is that some smoking signals are cell subtype
specific [68, 69], potentially reflecting a selective en-
hancement of activated cells, because smoking can also
induce changes in blood count [70]. In adipose tissue,
this particular effect may be represented as an infiltra-
tion of activated NK cells, and this infiltration may in-
crease with obesity, diabetes, and smoking. On the
other hand, the relative abundance of NK DNA com-
pared with adipose DNA in adipose tissue is minimal;
therefore, these effects should be minimal. Future studies
are needed to assess the impact of these potential con-
founding effects using for example histological and im-
munological staining of adipose tissue.
Conclusion
Our results show that smoking can impact DNA methy-
lation and gene expression levels in adipose tissue. To
our knowledge, this is the first study that performed
genome-wide analyses of smoking in adipose tissue
DNA methylation and gene expression profiles. The key
results are that, first, smoking leaves a signature on both
the methylome and transcriptome with overlapping sig-
nals; second, smoking methylation signals tend to be
tissue-shared effects; third, smoking has a longer lasting
influence on DNA methylation levels than on gene ex-
pression after smoking cessation; and forth, specific
smoking methylation and expression signals are associ-
ated with metabolic disease risk phenotypes, as well as
future weight gain after smoking cessation.
Methods
Study population and sample collection
The primary sample of subjects is twins from the
TwinsUK cohort who were recruited as part of the
MuTHER (Multiple Tissue Human Expression Resource)
study [71]. All subjects are Caucasian females and ascer-
tained to be free from severe disease when the samples
were collected. The sample consisted of 542 female twins,
comprising 54 current smokers, 197 ex-smokers, and 291
non-smokers. The 542 twins included 84 MZ twin pairs,
112 DZ twin pairs, and 150 unrelated individuals (Add-
itional file 2: Table S6). Adipose tissue biopsies were ob-
tained from all subjects between August 2007 and May
2009. Details of biopsy procedures and sample descrip-
tions are described previously [72]. Briefly, subcutaneous
adipose tissue biopsies were dissected from near the um-
bilicus of the abdominal region; the fat layer was separated
from skin layers and stored immediately in liquid nitro-
gen. Both DNA and RNA were extracted from the same
adipose tissue biopsy, as previously described [72, 73].
Ethical approval was granted by the National Research
Ethics Service London-Westminster, the St Thomas’
Hospital Research Ethics Committee (EC04/015 and
07/H0802/84). All research participants have signed an
informed consent prior to taking part in any research
activities.
To explore tissue-shared effects, peripheral blood sam-
ples from 789 and 362 subjects from TwinsUK were also
explored for genome-wide methylation and expression
profiling, respectively. The blood samples for methyla-
tion measurement were taken from 1992 to 2012, and
the samples for gene expression measurement were
taken from 2007 to 2009. From the 542 subjects with
available adipose tissue samples, 200 and 222 subjects
donated blood samples for methylation and expression
profiling, respectively. Blood samples and adipose tissues
were collected during the subject’s visit to the clinic.
The majority of data analysis focused on methylation and
expression level differences between current smokers and
non-smokers. The sample subsets of current smokers and
non-smokers comprised 345 subjects in adipose methyla-
tion and expression samples, 567 subjects in blood methy-
lation samples, and 237 in blood expression samples.
Replication and validation analyses
The 42 smoking-DMS that we identified in the TwinsUK
cohort were further explored in five independent data-
sets: (1) 104 subjects from the LEAP cohort were used
for adipose smoking-DMS replication (dataset 1); (2) 69
subjects from the Finnish Twins were used for replica-
tion of methylation associations with metabolic pheno-
types (dataset 2); and (3) 195 subjects (skin, dataset 3),
(4) 168 subjects (lung, dataset 4), and (5) 567 subjects
(blood, dataset 5) were used to explore tissue-shared
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effects at the 42 smoking-DMS. Details of dataset 5 were
described in the previous section.
Dataset 1: LEAP cohort adipose tissue (USA)
To replicate the 42 adipose tissue smoking-DMS, we
studied 104 participants from the New England Family
Study, the LEAP cohort (mean BMI 30.9 ± 7.03, mean
age 47 ± 1.7, 48% male; see Additional file 2: Table S6),
described in detail elsewhere [39]. The individuals are of
mixed ancestry (63.5% white) and were not affected with
disease. There were 46 current smokers and 58 non-
smokers. Subcutaneous adipose tissue samples in these
participants were collected from the upper outer quadrant
of the buttock, followed by DNA extraction, and Infinium
HumanMethylation450 BeadChip array profiling as previ-
ously described [37]. Replication analyses were performed
using a linear regression model adjusting for age, gender,
BMI, and batch effect.
Dataset 2: Finnish twin adipose tissue
To replicate the methylation associations with metabolic
health traits, we studied 69 Finnish twins (mean age
31.1 ± 4.43 years, mean BMI 27.5 ± 4.72, 44.9% male; see
Additional file 2: Table S6), who were recruited as a part
of the Finnish twin cohort. Adipose tissue sample collec-
tion and DNA extraction in this sample have been previ-
ously described in detail [74, 75]. The sample included
34 full MZ twin pairs and 21 current smokers. DNA
methylation profiling was measured by Infinium
HumanMethylation450 BeadChip array and TFM and
AGR were determined by dual energy X-ray absorpti-
ometry (DEXA). Replication analyses were performed
using a linear mixed effect regression model adjusting
for age, gender, BMI, family, batch effect, and alcohol in-
take. Sample characteristics of the replication cohorts
are shown in Additional file 2: Table S6.
To examine the tissue specificity of the 42 smoking-
DMS, we included two additional datasets (dataset 3 and
dataset 4) for validation of tissue-shared smoking effects.
Dataset 3: TwinsUK skin tissue
The first validation dataset for identifying tissue-shared
effects included 195 skin tissue samples from twins
(mean age 59.1 ± 9.71 years, mean BMI 26.7 ± 4.71; see
Additional file 2: Table S6) from the TwinsUK cohort.
This analysis included 37 current smokers and 158 non-
smokers cancer-free female subjects only, and some sub-
jects also provided adipose samples in the current study.
The TwinsUK skin samples and the evaluation of DNA
methylation in the samples are described elsewhere [34].
We performed the analysis using a linear mixed effects
model adjusting for age, BMI, alcohol consumption, batch
effect, family structure, and zygosity. Sample characteristics
are shown in Additional file 2: Table S6.
Dataset 4: Lung cancer tissue
The second validation dataset for identifying tissue-shared
smoking effects included 168 lung cancer female subjects
(mean age 65.1 ± 10.66 years; see Additional file 2:
Table S6) from a multicenter cohort of 450 subjects
with non-small cell lung cancer (GEO dataset: GSE39279)
[76]. In the validation analysis, we selected only female
subjects who had smoking records (129 current smokers
and 39 non-smokers) and used a linear regression model
to test for the effect of smoking on methylation, adjusting
for age, cancer stage [1 to 4], and cancer type (adeno-
carcinoma or squamous). DNA methylation levels were
obtained using the Infinium HumanMethylation450
BeadChip, and BMIQ normalization was performed
prior to analysis.
Phenotype collection
During a subject’s clinical visit, basic demographic infor-
mation was collected, with on-site measurements such
as height and weight, DEXA measurements, and biopsy
collection. Self-reported smoking status is obtained
through longitudinal questionnaires. Data included an-
swers to the following questions: “Do you currently
smoke (more than 3 days per week)?” (yes/no), “How
long has it been since you gave up smoking (in years/
months)?”, “How long have you smoked for in total (in
years/months)?”, “On average how many cigarettes do
you smoke a day (cigarette numbers)?”, “How many
cigarette you smoke in the past 100 days (cigarette
numbers)?”. Longitudinal data were available for each
subject, and we excluded subjects who did not have
consistent longitudinal smoking records. Smoking sta-
tus was defined in three categories: current smokers,
ex-smokers, and non-smokers. Current smokers were
defined as subjects who consistently smoked cigarettes
(and have not stopped at any point) according to their
longitudinal records up to the clinical visit when the
adipose tissue biopsy was obtained. Ex-smokers were
individuals who have successfully (and consistently) re-
ported to have quit smoking cigarettes for at least
3 months prior to the adipose tissue biopsy. Non-smokers
were individuals who never smoked according to the lon-
gitudinal questionnaire records. Other phenotypes such as
age, body mass index (BMI), and alcohol consumption
were also collected during the clinical visit. The alcohol
consumption data were obtained by questionnaires, and
subjects were asked about the quantity (mL) and beverage
types (beer, cider, lager, wine, spirits) drank per week. We
then summarized the total alcohol intake as units per
week and then converted to grams/day (one unit of alco-
hol in the UK is defined as 7.9 g [77]). Adiposity pheno-
types, such as total fat mass (TFM), visceral fat mass
(VFM), and android-to-gynoid ratio (AGR) were mea-
sured by DEXA scan.
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Some participants have regular clinical research visits,
approximately every 2 years. To study the weight gain
after smoking cessation, we used phenotype information
for VFM collected at two time points: the first time
point is the date nearest to the adipose tissue collection
date, and the second time point is the most recent clin-
ical research visit of the subject where VFM data were
collected. The time between longitudinal clinical re-
search visits used in this study ranged between 3 and
7 years with a mean of 5.1 ± 0.70.
Genome-wide DNA methylation profiles
The Infinium HumanMethylation450 BeadChip (Illumina
Inc., San Diego, CA) was used to measure DNA methyla-
tion in both adipose and blood samples. Details of experi-
mental approaches have been previously described [72, 78].
At each probe, the methylation levels are characterized as
a finite bounded quantitative trait ranging between 0 and
1, and represented as beta values. To overcome biases
caused by the two Illumina probe types and two-color
channels [79], we performed the beta mixture quantile
dilation (BMIQ) method [80] and background correction
for each sample. DNA methylation probes that mapped
incorrectly or to multiple locations in the reference se-
quence were removed. Probes with more than 1% of sub-
jects with detection P value > 0.05 were also removed. All
the probes have non-missing values in blood samples and
less than 1% missing subjects in adipose samples. Probes
located on chromosomes X and Y were removed from the
analysis. To check for sample swaps, we compared 65 sin-
gle nucleotide polymorphism (SNP) markers that featured
as control probes on the array to genotypes for each sub-
ject and removed subjects with incomparable genotypes.
Because methylation levels on the majority of probes do
not follow the normal distribution, which might violate
the regression assumption for downstream analysis, we
normalized the methylation levels to N(0,1) prior to ana-
lysis. For all the other methylation datasets (USA adipose,
Finnish adipose, lung cancer tissues, TwinsUK skin sam-
ples, and TwinsUK blood samples), we performed exactly
the same quality control steps for data cleaning and
normalization prior to the analysis.
RNA-sequencing data
The twin adipose RNA-seq data and quality control have
been previously described [81, 82]. Briefly, sequenced
paired-end reads (49 bp) were mapped to the human
genome (GRCh37) by Burrows-Wheeler aligner (BWA)
software v0.5.9 [83], then genes were annotated as de-
fined by protein coding in GENCODE v10 [84]. Samples
were excluded if they failed during library preparation or
sequencing. Samples were only considered to have good
quality if more than 10 million reads were sequenced
and mapped to exons. Gene expression levels were
quantified per gene, estimated as RPKM values (reads
per kilobase of transcript per million mapped reads) and
rank normal transformed prior to analysis. The genotype
of each subject was used for identity checks in case of
sample swaps. After removing genes located on chromo-
somes X and Y, and non-coding transcripts, 17,399
genes were included in the gene expression analysis for
adipose tissues and blood samples.
Genotype data
Genotypes were available for all subjects in study. Geno-
typing of the larger TwinsUK dataset was performed
using HumanHap300, HumanHap610Q, HumanHap1M
Duo, and HumanHap1.2M Duo 1M arrays. Imputation
was done in two datasets separately and subsequently
merged with GTOOL. Genotype data were pre-phased
using IMPUTE2 without a reference panel, then using
the resulting haplotypes to perform fast imputation from
1000 Genome phase1 dataset [85, 86]. We used 1000
Genomes Phase I (interim) as reference set, based on a
sequence data freeze from 23 Nov 2010; the phased hap-
lotypes were released Jun 2011. After imputation, SNPs
were filtered at a MAF > 5%. Genotypes were used for
identification of meQTLs and eQTLs in the 542 adipose
samples.
Statistical analysis
Differential methylation and expression analyses
Principal component analysis (PCA) was used to identify
potential batch effects and covariates to be included in the
statistical model for both methylation and gene expression
adipose data. To identify the adipose methylation differ-
ences between current smokers and non-smokers, a linear
mixed effect regression model (LMER) was applied adjust-
ing for batch effects (plate, position on the plate, bisulfite
conversion levels, and bisulfite conversion efficiency), age,
BMI, alcohol consumption, family and zygosity structure.
In the blood, the methylation differences between current
smokers and non-smokers were tested adjusting for batch
effects (plate and position on the plate), age, BMI, alcohol
consumption, and seven predicted cell count estimates
(plasma blast, CD8pCd28nCD45Ran, CD8 naïve, CD4T,
NK, monocytes, and granulocytes), family and zygosity
structure. Blood cell counts were calculated using the
Horvath online calculator [87]. A linear mixed effect re-
gression model was applied as the data contained MZ and
DZ twins. Family structure and zygosity were included as
random effect terms, while all the other covariates were
included as fixed effect terms. Similarly, in the RNA-seq
data analysis, the adipose and blood expression differences
between current smokers and non-smokers were exam-
ined using LMER adjusting for age, BMI, alcohol con-
sumption (grams/day), GC mean, primer index, clinic visit
date, family structure, and zygosity. Family structure,
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zygosity, primer index, and clinic visit date were taken as
random effect, and all the other covariates were included
as fixed terms. For each CpG site or gene, a full model
that regressed all of the covariates was compared to a null
model that excluded smoking status. The models were
compared using the ANOVA F statistic. A genome-wide
significance level was set at 1% false discovery rate for all
analyses.
In order to account for mixtures of cell types in adipose
tissue, we performed a EWAS using the reference-free ap-
proach proposed by Houseman et al. [32]. The method is
similar to surrogate variable analysis (SVA) and inde-
pendent surrogate variable analysis (ISVA), which is
used to adjust for technical errors (e.g., batch effect)
and confounders. In addition, the reference-free ap-
proach also includes a bootstrap step to account for the
correlation in the structure of standard errors. Using
this approach, we can estimate direct epigenetic effects
that account for cell compositions and use bootstrap-based
P values to assess their significance. Due to the limitation
that the reference-free approach can currently only be ap-
plied to datasets of unrelated individuals, we used 251 unre-
lated individuals from the original 542 twins and compared
the top results between two EWASs.
To identify tissue-shared smoking differentially meth-
ylated signals across adipose and whole blood datasets,
we compared the genome-wide FDR 1% signals across
adipose and whole blood DNA methylation analyses. In
whole blood samples, we tested for association between
smoking status and DNA methylation levels at 452,874
CpG sites in 86 current and 481 non-smokers in blood.
We compared the FDR 1% adipose DMS to 2782 CpG
sites that were associated with smoking in blood at
FDR 1% (P = 1.14 × 10−5). To further explore tissue spe-
cificity in other tissues, we explored the 14 tissue-
shared smoking-DMS identified in both adipose and
blood samples. We used previously published datasets
of 196 cancer-free female subjects with skin tissue biop-
sies [34] and a lung cancer DNA methylation dataset
[76], applying a Bonferroni-adjusted P value of 3.6 × 10−4
as the significance threshold.
Receiver operative curve (ROC) analysis
We tested several models for predicting smoking status
based on the different combinations of the adipose
smoking-DMS and smoking-DES. The sensitivity and
specificity of these prediction models were calculated
using receiver operative curve (ROC). The ROC analysis
was performed in R using the “pROC” package [88] with
the “lme” function for logistic regression, where outcomes
are categorized as current smokers and non-smokers. We
then used the “predict” function to predict the expected
probabilities under different combinations of predicting
factors (methylation levels of 14 CpG sites and expression
levels at five genes), and the “roc” function to predict
the sensitivity and specificity and draw the area under
the curve. We selected 27 current smokers and 145
non-smokers as a training set to construct a logistic
model for smoking status classification, and then used
the remaining set of 173 subjects (27 current smokers)
as a validation set, in which we obtained the AUC values.
We repeated this procedure 1000 times and report the
average AUC values across 1000 validation sets.
Smoking cessation analyses
We quantified “reversal” time by estimating the time (in
smoking-quit years) required for ex-smokers to revert to
25% of the change in methylation towards non-smokers.
We first calculate the difference between methylation
levels in current smokers and those in non-smokers
and use 25% change of that difference as a “reversal”
threshold. For example, at cg05575921 in AHRR, the
median level of methylation residual is − 0.234 in
current smokers and 0.037 in non-smokers, resulting in
a 0.271 methylation change. Therefore, ex-smokers who
reached methylation levels of − 0.031 were classified as
subjects who “reversed”. We quantified the proportion
of subjects who reversed within different quit years. For
example, at cg05575921, 6 ex-smokers quit in less than
1 year, but only one had methylation reverting to 25%
of the methylation change towards non-smokers; there-
fore, the reversal rate was 16.7%. We quantified reversal
at the gene expression level using the same approach.
Methylation QTL (meQTL) analyses
Genome-wide meQTL analyses were performed testing
for the association between common genetic variants
and DNA methylation at CpG sites in the two adipose
tissue samples. We only considered SNPs that were sig-
nificantly associated with DNA methylation in cis to be
meQTLs. If multiple SNPs were identified for a single
CpG site, we reported only the most significant SNP per
CpG site (P = 5 × 10−5, as described in Grundberg et al.
[72]). In total, methylation levels of 102,461 CpG sites
were associated with genetic factors in cis, and 25,531
sites in trans.
We tested for adipose tissue meQTLs first by fitting a
LME model regressed all the identified covariates, then
performed a linear regression of the residuals on the
SNPs using the MatrixeQTL R package [89]. Results
from meQTL analyses are presented at a P value of 10−5
for the smoking-DMS, the smoking-DES, and at the
smoking GWAS genetic variants. For meQTL analyses
replicating the results from Loukola et al. [43], we ap-
plied a different threshold. Loukola et al. [43] conducted
a genome-wide association study of nicotine metabolite
ratio, identifying many strongly associated SNPs in a
4.2-Mb region on chromosome 19q13. Among the 158
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CpG sites within that region, 16 CpG sites showed sta-
tistically significant association with 173 SNPs. We com-
pared our meQTL findings to those from Loukola et al.
[43] at a modified Bonferroni significance threshold of
1.81 × 10−5 (= 0.05/(16 × 173)) and identified SNPs that
influence methylation levels at 5 CpG sites (in CYP2A7,
ENGL2, and LTBP4 genes) (Additional file 2: Table S5).
Correlations between methylation and gene expression
levels
We compared the 542 subjects’ adipose methylation and
gene expression levels at the five overlapping genes iden-
tified in the two genome-wide association analyses. Both
the methylation and expression data were first adjusted
for covariates, and Spearman’s correlation test was then
performed on the residuals.
Metabolic disease risk phenotype analyses
We studied the impacts of smoking methylation signals
on obesity and metabolic phenotypes. We explored 288 adi-
pose subjects (42 current smokers and 246 non-smokers,
mean BMI = 26.70 ± 4.62) who had available DEXA profiles
at or within up to 1 year of the adipose tissue biopsy. We
compared the association between DNA methylation and
the adiposity phenotypes, such as visceral fat mass (VFM),
total fat mass (TFM), and android-to-gynoid fat ratio
(AGR). Analyses were carried out at the 42 smoking-DMS
using a linear regression model adjusting for BMI, age,
and smoking status. A significance level was set at a
Bonferroni-adjusted threshold of P = 5.7 × 10−4. We
used a similar approach to test for phenotype associa-
tions with the 42 smoking-DES.
To further investigate the effect of 42 smoking-DMS
and 42 smoking-DES on weight gain after smoking ces-
sation, the adiposity phenotype differences were ob-
tained at two time points in a reduced sample size of
248 subjects. Depending on a subjects’ smoking behavior
at the two time points, we categorized subjects into five
categories: current smokers at the two time points (con-
stant smokers, S-S, n = 12), current smokers at time
point 1 who quit smoking by time point 2 (S-E, n = 5),
ex-smokers (who quit smoking within 1–5 years) at time
point 1 who remain ex-smokers at time point 2 (E1-E5,
n = 13), ex-smokers who quit > 5 years at time point 1
who remain ex-smokers at time point 2 (E5+, n = 92),
and non-smokers at both time points (never smokers,
N-N, n = 124). We then calculated the phenotype differ-
ences (phenotype at time point 2 minus phenotypes at
time point 1) for each subject and correlated this differ-
ences to their adipose methylation (42 smoking-DMS)
and gene expression levels (42 smoking-DES).
We used the R statistical software (https://www.r-projec-
t.org/) for all analyses and figures, and the regional plots
were generated using the coMET package [90].
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Additional file 1: Figure S1. Scatterplot of correlations between EWAS
-log10P-values from the linear mixed effect model used in the current study
adipose discovery sample (y-axis) and results from Reference-free EWAS
approach proposed by Houseman et al. (x-axis) [32]. Figure S2. Smoking
cessation and adipose DNA methylation profiles. DNA methylation levels at
the 42 smoking-DMS and smoking status in 542 adipose samples. Subject
groups include current smoker, subjects who quit smoking within one year,
subjects who quit between 1 to 5 years, subjects who quit smoking more
than 5 years, and subjects who never smoked. Fourteen CpG sites located
in genes with both smoking-DMS and smoking-DES are denoted with
asterisks. Figure S3. Smoking cessation and adipose gene expression
profiles. Gene expression levels at the 42 smoking-DES and smoking
status in 542 adipose samples. Subject groups include current smoker,
subjects who quit smoking within one year, subjects who quit between
1 to 5 years, subjects who quit smoking more than 5 years, and subjects who
never smoked. Five genes with both smoking-DMS and smoking-DES are
denoted with asterisks. Figure S4. Association between DNA methylation
levels at the 42 smoking-DMS and future change in visceral fat mass (VFM) in
18 (red solid dots) and 228 subjects (gray hollow dots). Figure S5. Association
between gene expression levels at the 42 smoking-DES and future change in
visceral fat mass (VFM) in 18 (blue solid dots) and 228 subjects (gray
hollow dots). (PDF 1411 kb)
Additional file 2: Table S1. Four smoking-induced differentially
methylated and expressed genes in blood samples. Table S2. Validation
of 14 tissue-shared smoking-DMS across four sample types. Table S3.
Replication of the 42 smoking-DMS in the LEAP cohort [39] with 104 current
smokers and non-smokers. Table S4. Previously-identified smoking genetic
variants and their impacts on DNA methylation and gene expression in
adipose tissue. Table S5. DNA methylation QTL (meQTLs) analyses at the
chromosome 19 region from Loukola et al. [43], showing replication in
TwinsUK adipose tissue samples. Table S6. Characteristics of TwinsUK
(adipose tissue, blood samples, and skin tissue [34]), Finnish cohort [74, 75],
LEAP cohort [39], and lung cancer [76] samples. (XLSX 43 kb)
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